Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor
Completed · Phase 2
Conditions studied: Obesity, Overweight, Craniopharyngioma
In brief
The purpose of this study is to determine whether exenatide can cause weight loss in patients with a history of craniopharyngioma or other brain lesion.
Key facts
- Study ID
- NCT01484873
- Run by
- Vanderbilt University Medical Center
- People needed
- 10
- Starts
- 2012-06-01
- Expected to finish
- 2015-03-01
- Last updated by the study team
- 2017-03-03
Who can join
Age: 18 and older, up to 40. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18 to 40 years old
- History of craniopharyngioma or other lesion in the hypothalamic region
- Greater than 6 months post-treatment, including chemotherapy, surgery or radiation
- BMI >30 mg/m2
- Females must be post-menopausal, surgically sterile or using effective birth control for at least 12 weeks
You may not qualify if…
- HgbA1C >7%
- Use of diabetes medications other than metformin in the past 12 weeks, including exenatide
- Use of weight loss drugs or initiation of a weight loss program in past 3 months
- Impaired renal function or history of kidney transplant
- History of gall stones (unless s/p cholecystectomy), pancreatitis or alcoholism
- Personal or family history of medullary carcinoma of the thyroid or MEN type 2
- History of gastroparesis or other gastric motility problems as exenatide decreases gastric motility
- History of allergic reaction to exenatide or other medication components
- Other significant comorbidities other than pituitary deficiencies
- Currently prescribed warfarin (exenatide may alter warfarin metabolism)
- Pregnant or lactating females
- History of severe hypoglycemia (BG <60 and requiring assistance from another person)
Where it is running
- Vanderbilt University — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.